Low virological response to interferon in children with chronic hepatitis C
- PMID: 10551382
- DOI: 10.1016/s0168-8278(99)80338-9
Low virological response to interferon in children with chronic hepatitis C
Abstract
Background/aims: Children with chronic hepatitis C were recently found to have higher rates of sustained response to interferon compared to adults. The aim of this study was to verify the response to interferon using frequent viremia measurements.
Methods: Sera from 25 children (13 males; mean age 7.9 years) with chronic hepatitis C, treated with recombinant alpha-2b interferon for 12 months, were tested for liver function tests and viremia levels for a median of 27.5 months. Autoantibodies were evaluated during and after interferon.
Results: Fifteen patients completed 12 months of interferon; treatment was stopped in 10 other patients. In 11 (44%) patients viremia was undetectable already at the second administration of interferon; one of them remained viremia-free up to the end of follow-up and had persistently normal alanine-aminotransferase levels (complete sustained responder). A complete sustained response was observed only in one other patient, who normalized alanine aminotransferase and cleared viremia from the 3rd month of therapy. Three patients with persistent viremia normalized alanine-aminotransferase from the 3rd week of therapy up to the end of follow-up (biochemical sustained responders). Viremia was undetectable during treatment in four patients, who stopped interferon because of worsening in hypertransaminasemia. Three of these four patients were anti-liver-kidney microsomal type 1-positive.
Conclusions: In this study the response rate to interferon was very low and viremia and transaminase findings were often discordant.
Similar articles
-
Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha-2b for chronic hepatitis type C. Results of a multicenter randomized trial.J Hepatol. 1997 Jul;27(1):56-62. doi: 10.1016/s0168-8278(97)80280-2. J Hepatol. 1997. PMID: 9252074 Clinical Trial.
-
Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy.Ann Intern Med. 1997 Nov 15;127(10):875-81. doi: 10.7326/0003-4819-127-10-199711150-00003. Ann Intern Med. 1997. PMID: 9382365
-
Quantitative viremia test for early prediction of a biochemical response in patients with chronic hepatitis C treated with interferon.J Chemother. 2001 Aug;13(4):424-8. doi: 10.1179/joc.2001.13.4.424. J Chemother. 2001. PMID: 11589486
-
Favorable response to lymphoblastoid interferon-alpha in children with chronic hepatitis C.J Hepatol. 1998 Feb;28(2):184-8. doi: 10.1016/0168-8278(88)80003-5. J Hepatol. 1998. PMID: 9514529 Clinical Trial.
-
Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.Rev Invest Clin. 2003 Mar-Apr;55(2):138-42. Rev Invest Clin. 2003. PMID: 12827916
Cited by
-
Treatment of hepatitis C in children: a systematic review.PLoS One. 2010 Jul 13;5(7):e11542. doi: 10.1371/journal.pone.0011542. PLoS One. 2010. PMID: 20644626 Free PMC article.
-
Design of the PEDS-C trial: pegylated interferon +/- ribavirin for children with chronic hepatitis C viral infection.Clin Trials. 2007;4(6):661-73. doi: 10.1177/1740774507085445. Clin Trials. 2007. PMID: 18042575 Free PMC article. Clinical Trial.
-
Hepatitis C virus infection in children coinfected with HIV: epidemiology and management.Paediatr Drugs. 2002;4(9):571-80. doi: 10.2165/00128072-200204090-00003. Paediatr Drugs. 2002. PMID: 12175272 Review.
-
Managing pediatric hepatitis C: current and emerging treatment options.Ther Clin Risk Manag. 2009 Jun;5(3):651-60. doi: 10.2147/tcrm.s5078. Epub 2009 Aug 20. Ther Clin Risk Manag. 2009. PMID: 19707281 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources